Syncona-backed Achilles Therapeutics recommends voluntary liquidation, return capital to shareholders

LONDON: Syncona Ltd, a leading life science investor, announced Monday that its portfolio company, Achilles Therapeutics plc, has recommended a members' solvent voluntary liquidation to return capital to shareholders. The…

NNR February 5, 2025

London Exchange

Syncona launches Beacon Therapeutics with £96 million financing to develop ophthalmic gene therapies

LONDON, UK: London-based healthcare company Syncona Ltd has announced the launch of Beacon Therapeutics Holdings Limited (Beacon Therapeutics), a leading ophthalmic gene therapy company. The company aims to restore and…

Ali Mirza June 12, 2023

London Exchange

Syncona invests £15mn in Oxford University spin out, OMass Therapeutics

LONDON, UK: Syncona Ltd it has committed £15 million in an oversubscribed £75.5 million Series B financing in OMass Therapeutics, a biotechnology company that identifies medicines against highly validated target…

Bernice Miles April 28, 2022

London Exchange

Novartis to buy Syncona’s Gyroscope Therapeutics for $1.5bn

LONDON, UK: Syncona Ltd has been reached to sell its portfolio company Gyroscope Therapeutics Holdings to Novartis for up to $1.5 billion on a cash and debt free basis. Novartis…

Bernice Miles December 22, 2021

London Exchange

Syncona co-leads Series B financing in Quell Therapeutics of up to $156 million

LONDON, UK: Syncona Ltd has committed $25 million (£19 million) to Quell Therapeutics, a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the…

NNR November 29, 2021

London Exchange

Syncona’s Achilles announces additional financing plans including IPO in USA

LONDON: Syncona’s portfolio company, Achilles Therapeutics has announced that it expects to consider additional capital raising options this year, which could include an initial public offering in the United States.…

NNR February 5, 2021